Drug overdose deaths are down in L.A. County in 2025. Here's why

For the third consecutive year, accidental drug overdose deaths have declined in Los Angeles County, falling from a peak of 3,220 in 2022 to 2,298 in 2025 — a nearly 30 percent reduction that public health officials attribute to sustained investment in harm reduction, treatment access, and community outreach.

The data, released Wednesday by the Los Angeles County Department of Public Health, shows a 6 percent year-over-year decline from 2024's 2,438 deaths. While that single-year drop is modest, the cumulative trend over three years represents one of the most significant sustained reductions in drug-related mortality in any major American metropolitan area.

**The numbers behind the trend**

The decline is not evenly distributed — and that's where the story gets more complicated.

Fentanyl-related deaths have fallen 40 percent since 2022, when the synthetic opioid overtook methamphetamine as the most common drug involved in overdose deaths countywide. Methamphetamine-related deaths declined 25 percent over the same period. Both substances remain the primary drivers of fatal overdoses, but the scale of the crisis has diminished measurably.

However, the data reveals a troubling exception. Deaths among adults aged 65 and older increased 14 percent in 2025, even as deaths across most other age groups declined. Adults 40 to 64 continue to account for the majority of overdose deaths — 53 percent of the total — and men continue to die at nearly four times the rate of women, with approximately 1,800 male deaths compared to just over 500 female deaths.

Racial disparities persist as well. Black residents continue to experience the highest overdose death rates in the county, and communities where more than 30 percent of residents live below the federal poverty level see significantly higher overdose rates than affluent areas.

**What's working**

Public Health Director Barbara Ferrer credited the sustained decline to three concurrent strategies: prevention, harm reduction, and treatment — delivered through community partnerships rather than top-down mandates.

The county's Fentanyl Frontline campaign has focused on distributing naloxone (Narcan) widely, training community members to recognize and respond to overdoses. The ByLAforLA.org platform connects residents with substance-use services while aiming to reduce the stigma that prevents people from seeking help. Outreach workers meet people where they are — a philosophy sometimes described as "no wrong door" — rather than requiring them to navigate complex intake systems.

This approach aligns with a growing body of evidence suggesting that harm reduction — including needle exchanges, naloxone distribution, and supervised consumption sites — saves lives without increasing drug use. Critics have argued these strategies enable addiction, but the data from Los Angeles County and national trends suggests otherwise.

**The national picture**

The local decline mirrors a broader national trend. Opioid overdose deaths across the United States have been falling since mid-2023, driven primarily by decreases in fentanyl-related fatalities, according to a recent KFF analysis. Multiple policy interventions have contributed: expanded access to overdose-reversal medication, increased treatment availability, and public awareness campaigns.

But the KFF report also flags emerging risks. Federal budget cuts, staffing reductions at health agencies, and diminished grant funding for state and local substance-use programs could reverse the progress. The shift toward enforcement-focused drug policy — including the designation of illicit fentanyl as a "weapon of mass destruction" — raises questions about whether the current harm-reduction infrastructure can survive under a different policy orientation.

**Why the decline might not last**

The 6 percent year-over-year drop is smaller than 2024's 22 percent decline, suggesting the easiest gains may have already been captured. The aging population using substances, the persistence of methamphetamine alongside fentanyl, and the emergence of xylazine (tranq) as a cutting agent all present ongoing challenges that naloxone alone cannot address.

Xylazine, a veterinary sedative increasingly found in the illicit drug supply, does not respond to naloxone because it is not an opioid. It causes severe skin ulcers and can depress breathing independently of any opioid effect. Its spread means that even as fentanyl deaths decline, a new class of medical emergencies may be replacing them.

**What this means for you**

If you have a family member or loved one struggling with substance use, the data from Los Angeles County offers cautious hope. Harm reduction works. Naloxone saves lives. Treatment access matters. But progress is fragile, and the policy environment at the federal level is shifting toward approaches that have not demonstrated the same evidence of effectiveness.

If you live in a community affected by the overdose crisis — and most American communities are — the lesson from LA County is that sustained, multi-pronged investment produces results. The decline didn't happen because of a single program. It happened because prevention, harm reduction, and treatment were all funded and coordinated simultaneously.

If you're a policymaker or public health professional, the data offers both validation and a warning. The three-year decline proves that the current strategy can work. The slowing rate of improvement, the worsening outcomes among older adults, and the threat of funding cuts all suggest that stopping now would be a mistake. The overdose crisis is receding, but it is far from over.